Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
Authors:
- Douglas G. JohnsDJDouglas G. Johns
- Louis-Charles CampeauLCLouis-Charles Campeau
- Puja BankaPBPuja Banka
- An BautmansABAn Bautmans
- Tjerk BuetersTBTjerk Bueters
- Elisabetta BianchiEBElisabetta Bianchi
- Danila BrancaDBDanila Branca
- Paul G. BulgerPBPaul G. Bulger
- Inne CrevecoeurICInne Crevecoeur
- Fa-Xiang DingFDFa-Xiang Ding
- Robert M. GarbaccioRGRobert M. Garbaccio
- Erik D. GuetschowEGErik D. Guetschow
Top Cited Papers
Open Access
- 1 May 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (2) , 144-158
Abstract
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. Methods: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). Results: MK-0616 displayed high affinity ( K i = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84–103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple–oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43–85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. Conclusions: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.Keywords
This publication has 30 references indexed in Scilit:
- mRNA display: from basic principles to macrocycle drug discoveryDrug Discovery Today, 2014
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 2012
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart DiseaseJACC, 2012
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol LevelsJACC, 2012
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialThe Lancet, 2012
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pHEMBO Reports, 2011
- Molecular basis of PCSK9 functionAtherosclerosis, 2009
- PCSK9 and LDL cholesterol: unravelling the target to design the bulletTrends in Biochemical Sciences, 2008
- Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9Journal of Lipid Research, 2008
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005